Business

Half of Bolt Biotherapy Strains with Mediocre Test Data from Investing.com

© Reuters.

By Sam Boughedda

Investing.com — Bolt biotherapy (NASDAQ :) Stock prices have fallen after mediocre interim data from early trials of the company’s leading immunostimulatory antibody complex, the drug.

Data on a drug called BDC-1001 were shared at the European Society for Medical Oncology Immuno-Oncology (ESMO IO) conference.

Bolt shares have fallen by more than 50.6% in the afternoon trading.

The company reported data from 57 subjects in a study spanning 16 HER2-expressing solid tumors. Her-2 is described by cancer.org as “a protein that helps the rapid growth of breast cancer cells.”

According to the company, BDC-1001 showed good safety and tolerability, showing early signs of clinical activity. In addition, early signs of clinical activity were seen in 13 of the 40 tumor-evaluable subjects.

“Bolt Biotherapeutics is committed to data-driven agile clinical development. This Phase 1/2 trial of BDC-1001 is a new candidate to mobilize the patient’s immune system to target tumors and their microenvironments. We have gained tremendous insight into our capabilities, “said Edith Perez, Bolt’s Chief Health Officer.

Disclaimer: Fusion media We inform you that the data contained on this website is not necessarily real-time or accurate. All CFDs (stocks, indices, futures) and forex prices are provided by the market maker, not the exchange, so prices may not be accurate and may differ from actual market prices. In other words, price is an indicator and is not suitable for trading purposes. Therefore, Fusion Media is not responsible for any transactional losses that may occur as a result of using this data.

Fusion media Alternatively, anyone involved with Fusion Media will not be liable for any loss or damage resulting from reliance on the data, quotes, charts, trading signals and other information contained on this website. Be fully informed about the risks and costs associated with financial market transactions. This is one of the most risky forms of investment possible.

Half of Bolt Biotherapy Strains with Mediocre Test Data from Investing.com

Source link Half of Bolt Biotherapy Strains with Mediocre Test Data from Investing.com

Related Articles

Back to top button